<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893252</url>
  </required_header>
  <id_info>
    <org_study_id>33737</org_study_id>
    <nct_id>NCT04893252</nct_id>
  </id_info>
  <brief_title>Vactosertib and Durvalumab in Gastric Cancer</brief_title>
  <official_title>Vactosertib in Combination With Durvalumab (MEDI4736) in Patients With Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hark Kyun Kim</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will test the efficacy and safety of durvalumab in combination with vactosertib in&#xD;
      patients with metastatic gastric cancers who failed ≥ 2 lines of chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy and safety of durvalumab (anti-PD-L1) via IV infusion Q4W, in combination with&#xD;
      vactosertib (TGF-beta inhibitor) PO bid for 5 days a week for up to a maximum of 12 months,&#xD;
      will be tested in patients with metastatic hypermutated gastric cancers as ≥ 3rd-line setting&#xD;
      until confirmed disease progression, unless there is unacceptable toxicity, withdrawal of&#xD;
      consent, or another discontinuation criterion is met.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Every 8 weeks from the date of the first dose until the date of progression, assessed up to 1 year</time_frame>
    <description>Objective response rate in 55 participants according to RECIST v1.1</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Stomach Neoplasm</condition>
  <arm_group>
    <arm_group_label>vactosertib in combination with durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single arm study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>durvalumab and vactosertib</intervention_name>
    <description>durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week)</description>
    <arm_group_label>vactosertib in combination with durvalumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have histologically- or cytologically-confirmed diagnosis of metastatic gastric&#xD;
             adenocarcinoma in the stomach and gastroesophageal junction that are refractory to at&#xD;
             least two lines of treatment.&#xD;
&#xD;
          -  Have a performance status of 0-1 on the ECOG Performance Scale.&#xD;
&#xD;
          -  Have measurable disease at least one investigator-assessed measurable disease per&#xD;
             RECIST v1.1&#xD;
&#xD;
          -  Have adequate organ functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior ALK5 inhibitor treatment&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose of study drugs&#xD;
&#xD;
          -  Patients weighing &lt;30kg&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hark K Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hark K Kim, MD,PhD</last_name>
    <phone>+82-31-920-2238</phone>
    <email>hkim@ncc.re.kr</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Hark Kyun Kim</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

